Clazakizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Other names | ALD518, BMS-945429 |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145239.02g·mol−1 |
Clazakizumab(formerlyALD518andBMS-945429), aninvestigational drug,is anaglycosylated,humanized rabbitmonoclonal antibodyagainstinterleukin-6.[1]Clazakizumab was developed byBristol Myers SquibandAlder Biopharmaceuticals.A preliminary randomized, double-blind,placebo-controlled,phase 2dose-ranging study of clazakizumab inpsoriatic arthritispatients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects ofpsoriatic arthritis;however, the antibody lacked adose-response effect.[2]
See also
[edit]- Tocilizumab(Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6,other anti-interleukin-6 agents
References
[edit]- ^Handbook of Therapeutic Antibodies, Volume 2.Wiley Blackwell. 2007. p. 987.ISBN9783527329373.RetrievedJanuary 23,2017.
- ^Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis".Arthritis Rheumatol.68(9): 2163–73.doi:10.1002/art.39700.PMID27059799.S2CID3644962.